A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

ClinicalTrials.gov ID: NCT01545453

Public ClinicalTrials.gov record NCT01545453. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.

Study identification

NCT ID: NCT01545453
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 205 participants

Conditions and interventions

Conditions

Asthma

Interventions

lebrikizumab Drug
placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 29, 2012
Primary completion: Jun 30, 2013
Completion: Jun 30, 2013
Last update posted: Nov 1, 2016

2012 – 2013

United States locations

U.S. sites: 62
U.S. states: 28
U.S. cities: 60

Facility	City	State	ZIP	Site status
Not listed	Oxford	Alabama	36203-7190	—
Not listed	Long Beach	California	90808	—
Not listed	Los Angeles	California	90025	—
Not listed	Orange	California	92868	—
Not listed	Redwood City	California	94063	—
Not listed	San Mateo	California	94401	—
Not listed	Stockton	California	95207	—
Not listed	Centennial	Colorado	80112	—
Not listed	Colorado Springs	Colorado	80907	—
Not listed	Kissimmee	Florida	34741	—
Not listed	Miami	Florida	33173	—
Not listed	Panama City	Florida	32405	—
Not listed	Columbus	Georgia	31904	—
Not listed	Decatur	Georgia	30033	—
Not listed	Woodstock	Georgia	30188	—
Not listed	Twin Falls	Idaho	83301	—
Not listed	Normal	Illinois	61761	—
Not listed	Indianapolis	Indiana	46208	—
Not listed	Lafayette	Indiana	47904	—
Not listed	Overland Park	Kansas	66210	—
Not listed	Baltimore	Maryland	21236	—
Not listed	Brockton	Massachusetts	02301	—
Not listed	Bay City	Michigan	48706	—
Not listed	Novi	Michigan	48375	—
Not listed	Ypsilanti	Michigan	48197	—
Not listed	Minneapolis	Minnesota	55402	—
Not listed	Plymouth	Minnesota	55441	—
Not listed	Chesterfield	Missouri	63017	—
Not listed	St Louis	Missouri	63141	—
Not listed	Missoula	Montana	59808	—
Not listed	Omaha	Nebraska	68130	—
Not listed	Brick	New Jersey	08724	—
Not listed	Edison	New Jersey	08820	—
Not listed	Ocean City	New Jersey	07712	—
Not listed	Teaneck	New Jersey	07666	—
Not listed	Verona	New Jersey	07044	—
Not listed	North Syracuse	New York	13212	—
Not listed	Canton	Ohio	44718	—
Not listed	Centerville	Ohio	45458	—
Not listed	Cincinnati	Ohio	45242	—
Not listed	Toledo	Ohio	43617	—
Not listed	Oklahoma City	Oklahoma	73120	—
Not listed	Tulsa	Oklahoma	74136	—
Not listed	Medford	Oregon	97504	—
Not listed	Altoona	Pennsylvania	16601	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Pittsburgh	Pennsylvania	15241	—
Not listed	Pittsburgh	Pennsylvania	PA	—
Not listed	Sellersville	Pennsylvania	18960	—
Not listed	Columbia	South Carolina	29201	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Austin	Texas	78750	—
Not listed	Austin	Texas	78759	—
Not listed	Boerne	Texas	78006	—
Not listed	El Paso	Texas	79903	—
Not listed	Houston	Texas	77030	—
Not listed	Sugar Land	Texas	77479	—
Not listed	Murray	Utah	84107	—
Not listed	Fairfax	Virginia	22030	—
Not listed	Spokane	Washington	99204	—
Not listed	Madison	Wisconsin	53715	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01545453, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01545453 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →